Truist Securities Downgrades Fulcrum Therapeutics to Hold, Lowers Price Target to $4
Benzinga Newsdesk 5 months ago
NewsDowngradesPrice TargetAnalyst Ratings
Truist Securities analyst Gregory Renza downgrades Fulcrum Therapeutics (NASDAQ:FULC) from Buy to Hold and lowers the price target from $17 to $4.
Truist Securities analyst Gregory Renza downgrades Fulcrum Therapeutics (NASDAQ:FULC) from Buy to Hold and lowers the price target from $17 to $4.